The role of ectonucleotidases CD39 and CD73 and adenosine signaling in solid organ transplantation

Frontiers in Immunology

Volumn 5, Issue FEB, 2014, Pages

  Roberts, Veena ^a   Stagg, John ^b   Dwyer, Karen M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adenosine; B cells; CD39; CD73; Treg

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; CD39 ANTIGEN; CD4 ANTIGEN; CD59 ANTIGEN; DECAY ACCELERATING FACTOR; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

B LYMPHOCYTE; BLOOD FLOW; CARDIAC ALLOGRAFT VASCULOPATHY; CD4+ T LYMPHOCYTE; CELL INFILTRATION; GENE EXPRESSION; GRAFT SURVIVAL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLAMMATION; INNATE IMMUNITY; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; NONHUMAN; ORGAN TRANSPLANTATION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 84895528947     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00064     Document Type: Review

References (74)

1. Dalloul AH. B-cell-mediated strategies to fight chronic allograft rejection. Front Immunol (2013) 4:444. doi: 10.3389/fimmu.2013.00444.
2. Saze Z, Schuler PJ, Hong C-S, Cheng D, Jackson EK, Whiteside TL. Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood (2013) 122(1):9-18. doi:10.1182/blood-2013-02-482406.
3. Yoshizaki A, Miyagaki T, Dilillo DJ, Matsushita T, Horikawa M, Kountikov EI, et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature (2012) 491(7423):264-8. doi:10.1038/nature11501.
4. Deaglio S, Robson SC. Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv Pharmacol (2011) 61:301-32. doi:10.1016/B978-0-12-385526-8.00010-2.
5. Eltzschig HK. Adenosine: an old drug newly discovered. Anesthesiology (2009) 111(4):904-15. doi:10.1097/ALN.0b013e3181b060f2.
6. Maliszewski CR, Delespesse GJ, Schoenborn MA, Armitage RJ, Fanslow WC, Nakajima T, et al. The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization. J Immunol (1994) 153(8):3574-83.
7. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood (2007) 110(4):1225-32. doi:10.1182/blood-2006-12-064527.
8. Deaglio S, Dwyer K, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 204(6):1257-65. doi:10.1084/jem.20062512.
9. Eltzschig HK, Thompson LF, Karhausen J, Cotta RJ, Ibla JC, Robson SC, et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood (2004) 104(13):3986-92. doi:10.1182/blood-2004-06-2066.
10. Kaczmarek E, Koziak K, Sevigny J, Siegel J, Anrather J, Beaudoin A, et al. Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem (1996) 271(51):33116-33122. doi:10.1074/jbc.271.51.33116.
11. Bours MJL, Swennen ELR, Di Virgilio F, Cronstein BN, Dagnelie PC. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther (2006) 112(2):358-404. doi:10.1016/j.pharmthera.2005.04.013.
12. Resta R, Yamashita Y, Thompson LF. Ecto-enzyme and signaling functions of lymphocyte CD 7 3. Immunol Rev (1998) 161(1):95-109. doi:10.1111/j.1600-065X.1998.tb01574.x.
13. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine. J Immunol (2006) 177(10):6780-6.
14. Hasegawa T, Bouis D, Liao H, Visovatti SH, Pinsky DJ. Ecto-5' nucleotidase (CD73)-mediated adenosine generation and signaling in murine cardiac allograft vasculopathy. Circ Res (2008) 103(12):1410-21. doi:10.1161/CIRCRESAHA.108.180059.
15. Schena F, Volpi S, Caterina E, Faliti F, Penco S, Santi M, et al. Dependence of immunoglobulin class switch recombination in B cells on vesicular release of ATP and CD73 ectonucleotidase activity. Cell Rep (2013) 3(6):1824-31. doi:10.1016/j.celrep.2013.05.022.
16. Kinsey GR, Sharma R, Huang L, Li L, Vergis AL, Ye H, et al. Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury. J Am Soc Nephrol (2009) 20(8):1744-53. doi:10.1681/ASN.2008111160.
17. Kinsey GR, Huang L, Jaworska K, Khutsishvili K, Becker DA, Ye H, et al. Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection. J Am Soc Nephrol (2012) 23(9):1528-37. doi:10.1681/ASN.2012010070.
18. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Waltz DA, Keck BM, et al. Registry of the international society for heart and lung transplantation: twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant (2006) 25(8):869-79. doi:10.1016/j.healun.2006.05.002.
19. Valantine HA. Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant atheroma. Transplantation (2003) 76(6):891-9. doi:10.1097/01.TP.0000080981.90718.EB.
20. Enjyoji K, Sevigny J, Lin Y, Frenette PS, Christie PD, Esch JS II, et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med (1999) 5(9):1010-7. doi:10.1038/12447.
21. Imai M, Takigami K, Guckelberger O, Kaczmarek E, Csizmadia E, Bach FH, et al. Recombinant adenoviral mediated CD39 gene transfer prolongs cardiac xenograft survival. Transplantation (2000) 70(6):864-70. doi:10.1097/00007890-200009270-00003.
22. Koyamada N, Miyatake T, Candinas D, Hechenleitner P, Siegel J, Hancock WW, et al. Apyrase administration prolongs discordant xenograft survival. Transplantation (1996) 62(12):1739-43. doi:10.1097/00007890-199612270-00008.
23. Dwyer KM, Robson SC, Nandurkar HH, Campbell DJ, Gock H, Murray-Segal LJ, et al. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest (2004) 113(10):1440-6. doi:10.1172/JCI19560.
24. Imai M, Takigami K, Guckelberger O, Enjyoji K, Smith RN, Lin Y, et al. Modulation of nucleoside [correction of nucleotide] triphosphate diphosphohydrolase-1 (NTPDase-1)cd39 in xenograft rejection. Mol Med (1999) 5(11):743-52.
25. Eltzschig HK, Kohler D, Eckle T, Kong T, Robson SC, Colgan SP. Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood (2009) 113(1):224-32. doi:10.1182/blood-2008-06-165746.
26. Kohler D, Eckle T, Faigle M, Grenz A, Mittelbronn M, Laucher S, et al. CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation (2007) 116(16):1784-94. doi:10.1161/CIRCULATIONAHA.107.690180.
27. Cai M, Huttinger ZM, He H, Zhang W, Li F, Goodman LA, et al. Transgenic over expression of ectonucleotide triphosphate diphosphohydrolase-1 protects against murine myocardial ischemic injury. J Mol Cell Cardiol (2011) 51(6):927-35. doi:10.1016/j.yjmcc.2011.09.003.
28. Eckle T, Krahn T, Grenz A, Kohler D, Mittelbronn M, Ledent C, et al. Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation (2007) 115(12):1581-90. doi:10.1161/CIRCULATIONAHA.106.669697.
29. Eckle T, Hartmann K, Bonney S, Reithel S, Mittelbronn M, Walker LA, et al. Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia. Nat Med (2012) 18(5):774-82. doi:10.1038/nm.2728.
30. Lim SH, Lee S, Noda K, Kawamura T, Tanaka Y, Shigemura N, et al. Adenosine injection prior to cardioplegia enhances preservation of senescent hearts in rat heterotopic heart transplantation. Eur J Cardiothorac Surg (2013) 43(6):1202-8. doi:10.1093/ejcts/ezs509.
31. Bonner F, Borg N, Jacoby C, Temme S, Ding Z, Flogel U, et al. Ecto-5'-nucleotidase on immune cells protects from adverse cardiac remodeling. Circ Res (2013) 113(3):301-12. doi:10.1161/CIRCRESAHA.113.300180.
32. Bonner F, Borg N, Burghoff S, Schrader J. Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury. PLoS One (2012) 7(4):e34730. doi:10.1371/journal.pone.0034730.
33. Koeppen M, Harter PN, Bonney S, Bonney M, Reithel S, Zachskorn C, et al. Adora2b signaling on bone marrow derived cells dampens myocardial ischemia-reperfusion injury. Anesthesiology (2012) 116(6):1245-57. doi:10.1097/ALN.0b013e318255793c.
34. Fiser SM, Tribble CG, Long SM, Kaza AK, Kern JA, Jones DR, et al. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg (2002) 73(4):1041-7. doi:10.1016/S0003-4975(01)03606-2.
35. Ohtsuka T, Changelian PS, Bouis D, Noon K, Harada H, Lama VN, et al. Ecto-5'-nucleotidase (CD73) attenuates allograft airway rejection through adenosine 2A receptor stimulation. J Immunol (2010) 185(2):1321-9. doi:10.4049/jimmunol.0901847.
36. Gazoni LM, Laubach VE, Mulloy DP, Bellizzi A, Unger EB, Linden J, et al. Additive protection against lung ischemia-reperfusion injury by adenosine A2A receptor activation before procurement and during reperfusion. J Thorac Cardiovasc Surg (2008) 135(1):156-65. doi:10.1016/j.jtcvs.2007.08.041.
37. Reece TB, Ellman PI, Maxey TS, Crosby IK, Warren PS, Chong TW, et al. Adenosine A2A receptor activation reduces inflammation and preserves pulmonary function in an in vivo model of lung transplantation. J Thorac Cardiovasc Surg (2005) 129(5):1137-43. doi:10.1016/j.jtcvs.2004.11.042.
38. Reece TB, Laubach VE, Tribble CG, Maxey TS, Ellman PI, Warren PS, et al. Adenosine A2A receptor agonist improves cardiac dysfunction from pulmonary ischemia-reperfusion injury. Ann Thorac Surg (2005) 79(4):1189-95. doi:10.1016/j.athoracsur.2004.09.038.
39. Sharma AK, Laubach VE, Ramos SI, Zhao Y, Stukenborg G, Linden J, et al. Adenosine A2A receptor activation on CD4+ T lymphocytes and neutrophils attenuates lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg (2010) 139(2):474-82. doi:10.1016/j.jtcvs.2009.08.033.
40. Emaminia A, Lapar DJ, Zhao Y, Steidle JF, Harris DA, Laubach VE, et al. Adenosine A(2)A agonist improves lung function during ex vivo lung perfusion. Ann Thorac Surg (2011) 92(5):1840-6. doi:10.1016/j.athoracsur.2011.06.062.
41. Westall GP, Levvey BJ, Salvaris E, Gooi J, Marasco S, Rosenfeldt F, et al. Sustained function of genetically modified porcine lungs in an ex vivo model of pulmonary xenotransplantation. J Heart Lung Transplant (2013) 32(11):1123-30. doi:10.1016/j.healun.2013.07.001.
42. Sevigny CP, Li L, Awad AS, Huang L, Mcduffie M, Linden J, et al. Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition. J Immunol (2007) 178(7):4240-9.
43. Chhabra P, Wang K, Zeng Q, Jecmenica M, Langman L, Linden J, et al. Adenosine A(2A) agonist administration improves islet transplant outcome: evidence for the role of innate immunity in islet graft rejection. Cell Transplant (2010) 19(5):597-612. doi:10.3727/096368910X491806.
44. Lau CL, Zhao Y, Kron L, Stoler MH, Laubach VE, Ailawadi G, et al. The role of adenosine A2A receptor signaling in bronchiolitis obliterans. Ann Thorac Surg (2009) 88(4):1071-8. doi:10.1016/j.athoracsur.2009.06.032.
45. Zhao Y, Lapar DJ, Steidle J, Emaminia A, Kron IL, Ailawadi G, et al. Adenosine signaling via the adenosine 2B receptor is involved in bronchiolitis obliterans development. J Heart Lung Transplant (2010) 29(12):1405-14. doi:10.1016/j.healun.2010.07.005.
46. Hart ML, Gorzolla C, Schittenhelm J, Robson SC, Eltzschig HK. SP1-dependent induction of CD39 facilitates hepatic ischemic preconditioning. J Immunol (2010) 184(7):4017-24. doi:10.4049/jimmunol.0901851.
47. Hart ML, Much C, Gorzolla C, Schittenhelm J, Kloor D, Stahl GL, et al. Extracellular adenosine production by ecto-5'-nucleotidase protects during murine hepatic ischemic preconditioning. Gastroenterology (2008) 135(5):1739-1750e3. doi:10.1053/j.gastro.2008.07.064.
48. Sun X, Imai M, Nowak-Machen M, Guckelberger O, Enjyoji K, Wu Y, et al. Liver damage and systemic inflammatory responses are exacerbated by the genetic deletion of CD39 in total hepatic ischemia. Purinergic Signal (2011) 7(4):427-34. doi:10.1007/s11302-011-9239-6.
49. Chouker A, Ohta A, Martignoni A, Lukashev D, Zacharia LC, Jackson EK, et al. In vivo hypoxic preconditioning protects from warm liver ischemia-reperfusion injury through the adenosine A2B receptor. Transplantation (2012) 94(9):894-902. doi:10.1097/TP.0b013e31826a9a46.
50. Humar A, Kosari K, Sielaff TD, Glessing B, Gomes M, Dietz C, et al. Liver regeneration after adult living donor and deceased donor split-liver transplants. Liver Transpl (2004) 10(3):374-8. doi:10.1002/lt.20096.
51. Beldi G, Wu Y, Sun X, Imai M, Enjyoji K, Csizmadia E, et al. Regulated catalysis of extracellular nucleotides by vascular CD39/ENTPD1 is required for liver regeneration. Gastroenterology (2008) 135(5):1751-60. doi:10.1053/j.gastro.2008.07.025.
52. Schmelzle M, Duhme C, Junger W, Salhanick SD, Chen Y, Wu Y, et al. CD39 modulates hematopoietic stem cell recruitment and promotes liver regeneration in mice and humans after partial hepatectomy. Ann Surg (2013) 257(4):693-701. doi:10.1097/SLA.0b013e31826c3ec2.
53. Day YJ, Marshall MA, Huang L, Mcduffie MJ, Okusa MD, Linden J. Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: inhibition of chemokine induction. Am J Physiol Gastrointest Liver Physiol (2004) 286(2):G285-93. doi:10.1152/ajpgi.00348.2003.
54. Day YJ, Li Y, Rieger JM, Ramos SI, Okusa MD, Linden J. A2A adenosine receptors on bone marrow-derived cells protect liver from ischemia-reperfusion injury. J Immunol (2005) 174(8):5040-6.
55. Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med (2006) 203(12):2639-48. doi:10.1084/jem.20061097.
56. Cao Z, Yuan Y, Jeyabalan G, Du Q, Tsung A, Geller DA, et al. Preactivation of NKT cells with alpha-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL-13 and adenosine A2A receptor. Am J Physiol Gastrointest Liver Physiol (2009) 297(2):G249-58. doi:10.1152/ajpgi.00041.2009.
57. Pommey S, Lu B, Mcrae J, Stagg J, Hill P, Salvaris E, et al. Liver grafts from CD39-overexpressing mice are protected from ischemia reperfusion injury due to reduced numbers of resident CD4(+) T cells. Hepatology (2013) 57(4):1597-606. doi:10.1002/hep.25985.
58. Roberts V, Lu B, Rajakumar S, Cowan PJ, Dwyer KM. The CD39-adenosinergic axis in the pathogenesis of renal ischemia-reperfusion injury. Purinergic Signal (2012) 9(2):135-43. doi:10.1007/s11302-012-9342-3.
59. Grenz A, Zhang H, Hermes M, Eckle T, Klingel K, Huang DY, et al. Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J (2007) 21(11):2863-73. doi:10.1096/fj.06-7947com.
60. Lu B, Rajakumar SV, Robson SC, Lee EK, Crikis S, D'Apice AJ, et al. The impact of purinergic signaling on renal ischemia-reperfusion injury. Transplantation (2008) 86(12):1707-12. doi:10.1097/TP.0b013e31819022bc.
61. Crikis S, Lu B, Murray-Segal LM, Selan C, Robson SC, D'Apice AJ, et al. Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am J Transplant (2010) 10(12):2586-95. doi:10.1111/j.1600-6143.2010.03257.x.
62. Grenz A, Zhang H, Eckle T, Mittelbronn M, Wehrmann M, Kohle C, et al. Protective role of ecto-5'-nucleotidase (CD73) in renal ischemia. J Am Soc Nephrol (2007) 18(3):833-45. doi:10.1681/ASN.2006101141.
63. Rajakumar SV, Lu B, Crikis S, Robson SC, D'Apice AJ, Cowan PJ, et al. Deficiency or inhibition of CD73 protects in mild kidney ischemia-reperfusion injury. Transplantation (2010) 90(12):1260-4. doi:10.1097/TP.0b013e3182003d9b.
64. Rittiner JE, Korboukh I, Hull-Ryde EA, Jin J, Janzen WP, Frye SV, et al. The nucleotide AMP is an adenosine A1 receptor agonist. J Biol Chem (2012) 287(8):5301-9. doi:10.1074/jbc.M111.291666.
65. Grenz A, Osswald H, Eckle T, Yang D, Zhang H, Tran ZV, et al. The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Med (2008) 5(6):e137. doi:10.1371/journal.pmed.0050137.
66. Grenz A, Bauerle JD, Dalton JH, Ridyard D, Badulak A, Tak E, et al. Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. J Clin Invest (2012) 122(2):693-710. doi:10.1172/JCI60214.
67. Day YJ, Huang L, Ye H, Li L, Linden J, Okusa MD. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: the role of CD4+ T cells and IFN-gamma. J Immunol (2006) 176(5):3108-14.
68. Li L, Huang L, Sung S-SJ, Lobo PI, Brown MG, Gregg RK, et al. NKT cell activation mediates neutrophil IFN-γ production and renal ischemia-reperfusion injury. J Immunol (2007) 178(9):5899-911.
69. Li L, Huang L, Ye H, Song SP, Bajwa A, Lee SJ, et al. Dendritic cells tolerized with adenosine A2AR agonist attenuate acute kidney injury. J Clin Invest (2012) 122(11):3931-42. doi:10.1172/JCI63170.
70. Linden J, Cekic C. Regulation of lymphocyte function by adenosine. Arterioscler Thromb Vasc Biol (2012) 32(9):2097-103. doi:10.1161/ATVBAHA.111.226837.
71. Kinsey GR, Huang L, Vergis AL, Li L, Okusa MD. Regulatory T cells contribute to the protective effect of ischemic preconditioning in the kidney. Kidney Int (2010) 77(9):771-80. doi:10.1038/ki.2010.12.
72. Dwyer KM, Hanidziar D, Putheti P, Hill PA, Pommey S, Mcrae JL, et al. Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am J Transplant (2010) 10(11):2410-20. doi:10.1111/j.1600-6143.2010.03291.x.
73. Chia JS, Mcrae JL, Thomas H, Fynch S, Elkerbout L, Hill P, et al. The protective effects of CD39 over-expression in multiple low dose streptozotocin-induced diabetes in mice. Diabetes (2013) 62(6):2026-35. doi:10.2337/db12-0625.
74. Chen J-F, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets-what are the challenges? Nat Rev Drug Discov (2013) 12(4):265-86. doi:10.1038/nrd3955.